NYXOAH SA - ORDINARY S

Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference

07 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones

06 Mar 2023 00:30:00 By Nasdaq GlobeNewswire

Nyxoah Announces Inaugural Investor & Analyst Meeting

22 Feb 2023 05:00:00 By Nasdaq GlobeNewswire

Nyxoah Announces Inaugural Investor & Analyst Meeting

21 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

09 Jan 2023 15:30:00 By Nasdaq GlobeNewswire

Information on the total number of voting rights and shares

29 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program

22 Dec 2022 15:12:14 By Nasdaq GlobeNewswire

Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference

17 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Reports Third Quarter 2022 Financial and Operating Results

08 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Nyxoah Announces Change to Board of Directors

24 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah to Participate in the Jefferies London Healthcare Conference

20 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

18 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Information on the total number of voting rights and shares

30 Sep 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

18 Aug 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

08 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

02 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

27 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

19 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Announces CE Mark Approval for Genio® 2.1

18 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients

11 Jul 2022 01:00:00 By Nasdaq GlobeNewswire